Pharmacokinetic and pharmacodynamic study of lenograstim for hematopoietic stem cell mobilization: a prospective randomized study for optimal apheresis

This study evaluated the correlation between the pharmacokinetics and pharmacodynamics of granulocyte colony‐stimulating factor (lenograstim) and the impact of initiation time of apheresis on stem cell mobilization in patients with multiple myeloma.

[1]  Peripheral , 2020, Definitions.

[2]  M. Qazilbash,et al.  Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy? , 2017, World journal of transplantation.

[3]  A. Krishnan,et al.  Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation , 2015, Bone Marrow Transplantation.

[4]  J. Dipersio,et al.  Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  H. Prince,et al.  Peripheral blood CD34+ cell enumeration as a predictor of apheresis yield: an analysis of more than 1,000 collections. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  T. Geiger,et al.  Prediction of CD34(+) cell yield in hematopoietic cell products from children by peripheral blood CD34(+) cell counts. , 2012, Cytotherapy.

[7]  C. Moore,et al.  Recommendations for Planning Pilot Studies in Clinical and Translational Research , 2011, Clinical and translational science.

[8]  J. Kim,et al.  Optimal timing of G-CSF administration for effective autologous stem cell collection , 2011, Bone Marrow Transplantation.

[9]  B. Barlogie,et al.  International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) , 2009, Leukemia.

[10]  A. Nademanee,et al.  Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. , 2009, Blood.

[11]  U. Ergene,et al.  Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT). , 2006, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[12]  D. Dingli,et al.  Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. , 2006, Clinical lymphoma & myeloma.

[13]  Steven A. Julious,et al.  Sample size of 12 per group rule of thumb for a pilot study , 2005 .

[14]  J. Huh,et al.  Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin’s lymphoma , 2005, Annals of Hematology.

[15]  N. Kröger,et al.  Kinetics of G–CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte‐stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study , 2004, Transfusion.

[16]  S. Fruehauf,et al.  It's moving day: factors affecting peripheral blood stem mobilization and strategies for improvement , 2003 .

[17]  P. Feugier,et al.  Hematologic recovery after autologous PBPC transplantation: importance of the number of postthaw CD34+ cells , 2003, Transfusion.

[18]  S. Fruehauf,et al.  It's moving day: factors affecting peripheral blood stem cell mobilization and strategies for improvement [corrected]. , 2003, British journal of haematology.

[19]  J. Kigawa,et al.  Timing of G-CSF Administration Based on the Circadian Rhythm in Patients With Ovarian Cancer , 2002, American journal of clinical oncology.

[20]  D. Follmann,et al.  Kinetics of G–CSF‐induced granulocyte mobilization in healthy subjects: effects of route of administration and addition of dexamethasone , 2002, Transfusion.

[21]  W. Leisenring,et al.  The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield , 1999, Transfusion.

[22]  Goldschmidt,et al.  The dose of granulocyte colony‐stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery , 1998, British journal of haematology.

[23]  J. Miguel,et al.  Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation , 1998, Transfusion.

[24]  D. Linch,et al.  Optimal timing for collection of PBPC after glycosylated G-CSF administration , 1998, Bone Marrow Transplantation.

[25]  A. Zelenetz,et al.  Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  M. Kauppila,et al.  Daily measurements of blood CD34+ cells after stem cell mobilization predict stem cell yield and posttransplant hematopoietic recovery. , 1997, Journal of hematotherapy.

[27]  R. Hargreaves,et al.  When to harvest peripheral-blood stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Roberts,et al.  Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. , 1995, Blood.

[29]  B. Barlogie,et al.  Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. , 1995, Blood.